Summary.-The humoral and cellular components of the antibody-dependent cellular cytotoxicity (ADCC) against allogeneic human colonic tumour cell lines were evaluated. The 2 colon cell lines used in this study non-cancer patients were tested, using the reaction with heterologous anti-CEA as positive control and as a reference point. In 46 cases (21 %) the sera were reactive in this system, and 43 of them were of Blood Group 0. However, there was no difference between the cancer patients and the normal controls. The antigenic determinant involved in this reaction is not the Blood Group A specificity but, most probably, a polypeptide common to CEA and A (as shown in the following publication). In addition, trials for the elimination of the non-tumour-specific reaction, by absorption or inhibition, failed to disclose a tumour-specific one. The value of the ADCC assay in monitoring human tumour immunity, and possible ways of eliminating reactivity to normal antigens in this system, are discussed in the light of these findings.
Summary.-The humoral and cellular components of the antibody-dependent cellular cytotoxicity (ADCC) against allogeneic human colonic tumour cell lines were evaluated. The 2 colon cell lines used in this study were found by immunofluorescence to have carcinoembryonic antigen (CEA) on their surface, and to become sensitive to the lytic effect of unstimulated lymphocytes after coating with heterologous anti-CEA. This reaction was used to evaluate the ADCC activity of mononuclear cells from the peripheral blood of patients with gastrointestinal cancer (mostly local extensive colo-rectal). Remarkable variability was found in the lytic capability (2-50% specific lysis) of both cancer and non-cancer mononuclear cells, with no significant difference between them. Sera from 127 cancer patients and 91 non-cancer patients were tested, using the reaction with heterologous anti-CEA as positive control and as a reference point. In 46 cases (21 %) the sera were reactive in this system, and 43 of them were of Blood Group 0. However, there was no difference between the cancer patients and the normal controls. The antigenic determinant involved in this reaction is not the Blood Group A specificity but, most probably, a polypeptide common to CEA and A (as shown in the following publication). In addition, trials for the elimination of the non-tumour-specific reaction, by absorption or inhibition, failed to disclose a tumour-specific one. The value of the ADCC assay in monitoring human tumour immunity, and possible ways of eliminating reactivity to normal antigens in this system, are discussed in the light of these findings.
ANTIBODY-DEPENDENT cellular cytotoxicity (ADCC) is a well defined in vitro reaction (Lovchik & Hong, 1977; Perlman, 1976) of unknown biological significance. The specificity of the reaction is determined by the antibodies that coat the target cells. The nonspecific cellular effector component is the K lymphocyte (Perlman, 1976) or sometimes the macrophage (Kohl et al., 1977) or polymorphonuclear leucocyte (Gale & Zighelboim, 1975) . All of them recognize the Fc portion of the coating antibody.
This reaction has been implicated in various in vivo immune processes, including those against tumours (Lamon et al., 1976) , virus-infected cells (Pearson & Orr, 1976) , transplants (Jeannet & Vassalli, 1976 ) and autoimmunity (Feldman et al., 1976) . However, although there is some evidence that ADCC does occur in these conditions, it has been impossible so far to demonstrate directly their relative importance among the multitude of immune reactions taking place in vivo. As far as tumour immunity is concerned, serum and lymphocyte cooperation was demonstrated in vitro in mice bearing Moloney sarcoma virus-induced or 3-methylcholanthreneinduced sarcomas and mammary-tumour virus-induced adenocarcinoma (Pollack et al., 1972) , as well as in rats with Gross virus-induced lymphoma (Ortiz de Landazuri et al., 1974) . Successful inhibition of murine neuroblastoma by ADCC was demonstrated in a modified Winn's test (Byfield et al., 1976) . With human tumours the condition is much less clear, and there are few publications suggesting that specific ADCC might occur in a limited number of cases (Kodera & Bean, 1975; Hellstrom et al., 1973; Hersey et al., 1973; Hakala & Lange, 1974) . However, the remarkable sensitivity of this reaction to low antibody levels (Zighelboim et al., 1973; Perlman, 1976) justify further evaluation of its applicability to the monitoring of antitumour activity in humans.
The present study was undertaken in order to use the ADCC reaction in the human colonic-tumour system using serum or lymphocytes from patients and matched controls against human colonic tumour cell lines. Our observations, and those of others (Von Kleist et al., 1975) (Thorsby & Bratlie, 1970) . Cells at interface were aspirated and washed x 3 in serum-free medium. These preparations contained 92-97% mononuclear cells, most of them (70-85%) with the morphological appearance of small lymphocytes. Such cell samples contained 54-7 + 10-2% and 50 7 + 117% E rosettes in normal adults and cancer patients respectively (Shoham et al., to be published), and 5-10% B rosettes (with mouse red blood cells). The "null" cell population was not further analysed for the presence of non-lymphocyte white blood cells (ZuckerFranklin, 1974; Currie et al., 1978) . Nevertheless, we will refer conventionally to these mononuclear cell preparations as peripheralblood lymphocytes (PBL) with the understanding that other white blood cells present in these preparations may contribute to the ADCC reaction (Kohl et al., 1977; Gale & Zighelboim, 1975 (Tables I and II) . This is the case with most of the PBL samples tested, but not with all (Fig. 3) . Similar results in both ADCC and CMC reactions were obtained with a second colonic tumour-cell line (ACC-20).
The ADCC reaction with anti-CEA is apparently immunologically specific (Table  II) (Fig. 1) . The lytic effect wvas detectable ul) to a I 000-fold diluition. In further experiments we used anti-CEA in a concentration of 1 mg/ml protein.
The lymphocyte-dose-dependency of the reaction is shown in Fig. 2 . There was a sharp decline in lysis when the number of lymphocytes was changed from 106 to 5 x 105 lymphocytes. The following experimenits were carried out with 106 PBL.
Patient lymphocytes as the tested variable PBL from 41 healthy subjects or noncancer patients and 25 with gastrointestinal (CI) cancer were tested in this assay for both ADCC against anti-CEA-coated HT-29 cells and CMC against uncoated cells (Fig. 3) . Most of the patients (21 /25) had local extensive large-bowel tumour without metastasis, and did not receive chemotherapy or radiotherapy at the test time. The score in Fig. 3 reflects the fact that the ability of PBL to participate in ADCC flulctuates from the barely measurable to about 60%o specific lysis. However, Here also we obtained a spectrum of activities from zero (equial to spontaneous release) to those approaching maximal release. However, the variability introduced by the lymphocytes (Fig. 3) precludes comparison of results with different lymphocyte preparation.
Pooling lymphocytes (usually from 2 donors) enabled us to conmpare larger numbers of seratunder uniform conditions without significantly changing the ADCC reactivity ( Fig. 3) and this served as a partial answer to this problem. It has to be mentioned, however, that CMC' of pooled PBL against uncoated HT-29 cells was significantly higher (P < 0 01) tha,n that of unpooled PBL. Moreover, anti-CEA wAas used as a reference serum for each PBL sample, and the results with the patients' sera were related to those of anti-CEA by dividing the°specific lysis (SL) of each one of the tested sera by that of anti-CEA. The results were regarded as the "cytotoxicity index" (CI). The CI of anti-CEA was, therefore, always I O( (Table III XVhen the results were correlated with the blood group of these subjects (Fig. 4) strated (Fig. 5) . The single positive Group AB serum was from multiparous women, and was found to contain HLA antibodies. The titre of the positive human sera was lower than that of anti-CEA, and approached background activity with dilutions of -A-or --l- (Fig. 6 ), without a difference between cancer and non-cancer sera, even when initially highly ADCCactive sera were selected.
DISCUSSION
The 2 components of the ADCC (cellular and humoral) were tested for their usefulness in the monitoring of human tumour immunity in allogeneic combination with colonic tumour cell lines.
As far as the cellular aspect is concerned, there is remarkable variability in the ability of mononuclear cells of different subjects to participate in the ADCC reaction. Such variability has also been found in other studies (Lovehik & Hong, 1977; Korithavongs et al., 1974) . However, the cells of healthy people and GI cancer patients do not differ in this characteristic in our system, which tests mostly patients with local extensive colo-rectal cancer. Other patients with more aclvanced (lisease also showed the same pattern of' distribution (data Inot shown). There is no agreement among other workers regarding this activity in cancer patients. The works of Lovehik & Hong (1977 ), Elhilali et al. (1976 and Peter et al. (1975a) support, our' observations, wrhereas Ting & Terasaki (1974) found (lepressed ADCC-effector activity in cancer patients. It, has to be emphasized that the Ficolle-Hypaqueseparated mononuclear cell preparations may contain substantial numbers of macrophages (Zucker-Franklin, 1974 ) and chloroacetate-esterase-positive cells and that the percentage of the last-mentionied cells may be especially high in cancer patients (Currie et al., 1978) . Although such cells may participate in ADCC (Kohl et al., 1977; GXale & Zighelboim, 1975) (Shoham & Cohen, 1979) , which brings evidence that the reaction observed is to an antigenic determinant common to CEA and A, and maybe normal colon antigen too. This determinant most probably resides in the protein portion of the molecule. The inhibition of this common activity did not expose tumour-specific activity. Lymphocyte dependent antibody (LDA) activity was looked for in other human tumour-cell systems. Hellstrom et al. (1973) showed increased lymphocytemediated tumour-cell destruction in their test systems with allogeneic combination of sera from 7 cancer patients (with different tumours) out of a "much larger patient material" (unspecified) with no reference to normal antigens. The same reservation applies to the work of Hakala & Lange (1974) , who found LDA activity in 2/40 transitional-cell carcinoma patients. In other publications a large panel of allogeneic target-tumour cells of the same histological type was used in order to solve the problem of immune specificity. Ferrone & Pellegrino (1977) used several melanoma cell lines in a complementdependent microcytotoxicity assay. They failed to find melanoma-specific activity as compared to serum activity in other cancer patients or correlation to disease stage. Hersey et al. (1973) found LDA in sera from AML patients to a panel of allogeneic AML myeloblasts, which they felt may be directed to a leukaemia-associated antigen. However, some of these patients had received immunotherapy with allogeneic cells, and all of them had been given multiple transfusions. Thus it is more plausible that the observed activity was related to HLA antigens. This notion is further supported by the recent work of Gale & MacLennan (1977) . Autochthonous combinations may avoid this confusion. Kodera & Bean (1975) used such combinations and found LDA activity in 4/16 patients, which was apparently related to disease state. A similar study by Peter et al. (1975b) in a smaller group of patients failed to show such activity. However, the numbers in the last 2 studies are too small to warrant any firm conclusion on the significance of this activity, and the difficulties encountered in using autochthonous combinations preclude their largescale use. An alternative approach is to eliminate the activity to HLA and bloodgroup antigens by selective absorption or by inhibition with Fab fragments of appropriate polyspecific serum. The potential of this approach is demonstrated in the following publication (Shoham & Cohen, 1979) . However, in the particular case of colonic tumour cells it failed to expose any specific tumour activity.
